Fresenius stock: FMC stake sale strengthens capital flexibility
Published on 11/12/2026 at 18:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFresenius completes stake sale
- Fresenius completed the sale of its Fresenius Medical Care shares through an accelerated bookbuild.
- The proceeds are intended to support investment in the group's growth platforms and strategic priorities.
- The transaction is expected to produce a special-item book gain in the fourth quarter.
Fresenius completed the sale of 13.4 million Fresenius Medical Care shares on Thursday, November 12, marking the execution of the transaction announced one day earlier. The company said in its investor release that the placing generated gross proceeds of approximately 524 million euros.
The shares were placed with institutional investors at 39.00 euros each through an accelerated bookbuild. Fresenius said its financial investment in Fresenius Medical Care will fall from approximately 25 percent to approximately 20 percent of issued share capital. Settlement is expected on Monday, November 16.
Capital allocation gains flexibility
Fresenius said the net proceeds will be available for its growth platforms and other priorities under the FutureFresenius strategy. Chief Financial Officer Sara Hennicken described the transaction as another step in the disciplined management of the Fresenius Medical Care investment and linked the released capital to the group's REJUVENATE phase.
The company expects a book gain in the low to mid double-digit million euro range. Fresenius said the gain will be recognized in fourth-quarter 2026 results as a special item. Its remaining Fresenius Medical Care shares are subject to a 90-day lock-up, subject to customary exceptions.
Fresenius stock remains near its high
Fresenius stock traded at 53.28 euros on Lang & Schwarz at 18:02 CET on Thursday, November 12, 0.02 percent below the Xetra close of Thursday, November 12. The completed sale gives Fresenius additional capital-allocation flexibility, while future investor assessment will depend on how the proceeds are deployed and on operating performance in its core businesses.
Fresenius stock at a glance
- Company: Fresenius SE & Co. KGaA
- ISIN: DE000FRE5EN2
- Ticker: FRE
- Home exchange: Xetra
- Lang & Schwarz price: 53.28 euros at 18:02 CET on Thursday, November 12, 2026
- Change versus Xetra close: 0.02 percent below the 53.29-euro close on Thursday, November 12, 2026
The DAX market environment remains the broader reference for Germany-listed healthcare shares.
